Eric E. Poma

Autre

Molecular Templates, Inc.Calidi Biotherapeutics, Inc.Innovive Pharmaceuticals, Inc.

Insider activity · 24 months1 buy0 salesCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 1 buy · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Companies

▲ Purchases (1 ops.)

€43k

▼ Sales (0 ops.)

—

Latest filing published 25 Aug 2025 for Calidi Biotherapeutics, Inc., €43k.

Filing timeline

BuySale

Eric E. Poma

Insider track record

Disclosed buys

Disclosed sells

Signal history

Closed purchases

Market purchases

Not enough history yet: 1 closed purchase, at least 2 are needed.

Purchases by company

Calidi Biotherapeutics, Inc. 1 purchase · last 25 Aug 2025

Since each purchase

Calidi Biotherapeutics, Inc.
Filed 25 Aug 2025 · 425 days ago · €43k
-95.0%
Entry US$27.20 · Close at T+365 US$1.35

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

Eric E. Poma: trading record in brief

Eric E. Poma has filed trades across 3 companies (mainly through SEC (Form 4)), most often in Molecular Templates, Inc., Calidi Biotherapeutics, Inc. and Innovive Pharmaceuticals, Inc. We count 7 filings; the first trade dates from 19 September 2008 and the latest from 21 August 2025.

On the market, this insider has only ever bought: 1 purchase, €43k in total. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 5 option exercises. 2025 to date brings 1 purchase and no sales.

Most recently, on 25 August 2025, the filings show an open-market purchase worth €43k in Calidi Biotherapeutics, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. For comparison, the SEC allows two business days to file a Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.